Shenzhen Beimei Pharmaceutical Co., LTD. (hereinafter referred to as "Beimei Pharmaceutical") has officially received the acceptance letter issued by the Drug Evaluation Center of the National Medical Products Administration.The sevelamercarbonate powder for oral suspension, which isimportedby Beimei Pharmaceutical,its application was accepted.In March 2022, Beimei ...

On April 1, 2022, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as "Beimei Pharmaceutical") and Netherlands Synthon B.V. (hereinafter referred to as " Synthon ") reached an exclusive license and supply agreement of a pharmaceutical product for the treatment of hyperphosphatemia (hereinafter referred to as "the product"). Under the te...

On February 24, 2022, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as "Beimei Pharmaceutical") and Dr. Reddy'slaboratory Ltd. (hereinafter referred to as "Dr. Reddy's") reached an exclusive license and supply agreement of a pharmaceutical product for the treatment of otic infection (hereinafter referred to as "the product"). ...

Shenzhen Beimei Pharmaceutical Co., Ltd. and MedPharm Ltd. (hereinafter referred to as "MedPharm") signed the Master Service Agreement (hereinafter referred to as the "Agreement") on 15th, Nov, 2021. According to the agreement, Beimei and MedPharm will cooperate in the development of a topical product for the treatment of immune diseases. MedPharm will be responsible for the preclinical research and development of products and technology transfer and will provide technical support for patent applications and product registrations. Beimei will have the exclusive right to commercialize the product in the global region, and will be responsible for the clinical study, registration, sales and promotion of the product and other commercialization activities.

Generic name:Atomoxetine Hydrochloride Oral SolutionDosage form:Oral SolutionRegistration category: Class 4The first self-developed product of Beimei, Atomoxetine Hydrochloride Oral Solution, with its dossier completion of pharmacological studies and registration data, has been filed to the Center for Drug Evaluation (CDE) of the National Medical Products Administration o...

The launch conference of Beimei Pharmaceutical’s 奥维平®Oselavir®came to a successful conclusionIn this season of harvesting joy and happiness, the launch of 奥维平® , with generic name of Oseltamivir Phosphate for Oral Suspension,was held in Shenzhen with great expectation. Experts, scholars, cooperative suppliers, agents and investors from all over the world gathered together to w...

On November 2, 2021, Shenzhen Beimei Pharmaceutical Co., LTD. ("Beimei Pharmaceutical") and LTS Lohmann Therapie-Systeme AG ("LTS") signed a Feasibility Study Agreement ("the Agreement"). Under this Agreement, Beimei Pharmaceutical will cooperate with LTS in assessing the feasibility of the development of an oral thin film product for ...

The Award Ceremony of 2021 Top 20 of Deloitte Shenzhen High-Tech High-Growth Groups and Rising Star Enterprises was successfully held On October 28 in 2021. Bemei Pharma was listed on the 2021 Shenzhen Rising Star Enterprises List.The Shenzhen Regional selection is co-sponsored by Deloitte China and Shenzhen Business Federation, aiming to discover and commend outstan...

奥维平®，whose generic name is Oseltamivir Phosphate for Oral Suspension, was formally approved by NMPA, the National Medical Products Administration recently.Oseltamivir Phosphate for Oral Suspension, as the first product forcooperation between Shenzhen Bemei Pharma and HETERO LABS LIMITED of India, its Regulatory application was officially accepted by the C...